Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441470 | 1.00 | GPR119 (0.53) | GPR119CA12CA14CA2EPHX1 | |
| SCHEMBL22445645 | 0.87 | CA12 (0.45) | GPR119CA12CA14CA2 | |
| SCHEMBL7653397 | 0.84 | GPR119 (0.56) | GPR119EPHX1STS | |
| SCHEMBL22407314 | 0.80 | CA12 (0.47) | GPR119CA12CA14CA2EPHX1 | |
| SCHEMBL22441449 | 0.79 | CA12 (0.46) | CA12CA14CA2EPHX1STS | |
| SCHEMBL7492043 | 0.77 | GPR119 (0.54) | GPR119EPHX1HPGD | |
| SCHEMBL7492047 | 0.77 | GPR119 (0.54) | GPR119EPHX1HPGD | |
| SCHEMBL23762384 | 0.77 | TGFBR1 (0.48) | CA12CA14CA2EPHX1HPGD | |
| SCHEMBL13600068 | 0.77 | GPR119 (0.56) | GPR119EPHX1HPGD | |
| SCHEMBL25819368 | 0.77 | GPR119 (0.56) | GPR119EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |